Eagle IP is excited to announce that Jennifer Che, President and Managing Director, will be attending the BIO 2025 International Conference, taking place from June 16-19 at the Boston Convention and Exhibition Centre. Jennifer will be participating in some events together with Hong Kong’s Science and Technology Park (HKSTP), who is hosting the Hong Kong Pavilion at BIO, sending a large delegation of attendees, as well as organizing several events.

This premier biotechnology event attracts over 17,000 professionals from around the globe, featuring networking opportunities, educational sessions, and an exhibition hall showcasing the latest innovations in the industry. Jennifer is looking forward to engaging with fellow attendees and exploring potential collaborations. She invites anyone attending the conference to reach out for a meeting to discuss opportunities, exchange ideas, or simply connect.

About BIO 2025
The BIO International Convention is the world’s largest biotechnology event, providing a platform for networking, learning, and collaboration. Attendees can participate in sessions covering the latest trends, regulatory updates, and scientific advancements, making it an invaluable experience for professionals in the biotech sector.

About Eagle IP
EAGLE IP is a specialized patent firm based in Greater China that facilitates the transfer of new technology from the research environment into the marketplace. Our team of Chinese and US patent practitioners possesses strong cross-border IP knowledge, industry experience, and deep technical expertise. We specialize in China patent strategy, patent drafting and prosecution, patent invalidations, cross-border IP issues, global patent portfolio strategy & management, and Hong Kong patent matters. Our management system is ISO 9001 certified for excellent quality control and management. Should you have any questions, please feel free to contact us at [email protected]

If you won’t be able to attend BIO 2025 but will be in Boston and would like to schedule a meeting, please let us know.

We are looking forward to seeing you in Boston!

我们的过去活动

Recommended Insights

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

2019年11月21日
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]

Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement

2024年1月9日
Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]

Hong Kong Launches New Original Grant Patent System

2019年12月17日
Hong Kong will be launching a new patent system on December 19, 2019 that includes key changes, most notably the introduction of an original grant patent system. This new patent system includes both the Patents (Amendment) Ordinance 2016 and the Patents (General) (Amendment) Rules 2019. Currently, there are two types of patent applications available in […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
Top crossarrow-right